PT-141 Spray | 30mg
$99.99
PT-141 (Bremelanotide) research spray — 30mg per 30ml bottle, 150–500mcg per actuation. Cyclic heptapeptide melanocortin receptor agonist. CAS 189691-06-3. HPLC-MS tested, >98% purity. Third-party tested, ISO 17025 verified. For research use only.
In stock (can be backordered)
- Description
- FDA Disclosure & Intended Use
- Storage Instructions
- Reviews (0)
- Research Use Only (RUO) Policy
Description
Description
Melanocortin Receptor Agonist · Research Grade · Performance →
PT-141 (Bremelanotide) Research Spray
Captide Labs PT-141 Spray delivers research-grade Bremelanotide in a pre-formulated, ready-to-use liquid spray format. Each 30ml bottle contains 30mg of PT-141 at greater than 98% purity, independently verified by HPLC-MS analysis and documented with a full Certificate of Analysis. Each actuation delivers 150–500mcg depending on application protocol.
PT-141 (CAS 189691-06-3), also known as Bremelanotide, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte stimulating hormone (α-MSH). It is the only research peptide with an FDA-approved indication specifically related to sexual function — approved in 2019 as Vyleesi® for hypoactive sexual desire disorder (HSDD) in premenopausal women. It operates through a mechanism entirely distinct from vascular-acting compounds, engaging melanocortin receptors in the central nervous system to modulate arousal and desire pathways.
|
Compound
PT-141 (Bremelanotide)
|
CAS Number
189691-06-3
|
|
Sequence
Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)
|
Purity
>98% (HPLC-MS Verified)
|
|
Molecular Formula
C₅₀H₆₈N₁₄O₁₀
|
Molecular Weight
1025.18 g/mol
|
|
Format
Liquid Spray
|
Concentration
1mg/ml (30mg / 30ml)
|
|
Spray Delivery
150–500mcg per actuation
|
Bottle Volume
30ml
|
|
Total Peptide
30mg
|
Testing Standard
ISO 17025 Accredited Lab
|
|
Storage
Refrigerate at 2–8°C. Do not freeze once in liquid form. Use within 28–30 days of opening.
|
|
What is PT-141?
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II research. It is a melanocortin receptor agonist with selective activity at MC3R and MC4R — receptors expressed primarily in the hypothalamus and limbic system, brain regions involved in motivation, reward, and arousal signaling. Unlike PDE5 inhibitors (sildenafil, tadalafil), which act peripherally on vascular smooth muscle, PT-141 acts centrally on the brain’s desire circuitry, representing a mechanistically distinct approach to sexual function research.
PT-141 was originally developed as a tanning agent derived from Melanotan II, but early clinical trials revealed its pronounced pro-sexual effects as a prominent finding. Subsequent development pivoted to sexual dysfunction research, culminating in FDA approval of Bremelanotide (Vyleesi®) in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the first and only melanocortin-based compound to achieve FDA approval for a sexual health indication.
Areas of active investigation
Frequently Asked Questions
For research use only. Not for human consumption, veterinary use, or food/agricultural applications. Not evaluated or approved by the FDA for research use. Not intended to diagnose, treat, cure, or prevent any condition. All purchases are made with the understanding that this compound is strictly for in-vitro research and laboratory use.
FDA Disclosure & Intended Use
FDA Disclosure: The statements on this website and the products sold herein have not been evaluated by the U.S. Food and Drug Administration (FDA). These products are not intended to diagnose, treat, cure, or prevent any disease. Products sold are for Research Use Only and are not for human or animal use.
Intended Purpose: Products sold on this site are intended solely for basic laboratory research, pharmaceutical research, or the development of new tests. They are not intended for diagnostic, therapeutic, or clinical use.
Storage Instructions
Handling and Storage Tips:
- Keep peptides cold and away from light once received.
- For short-term use (days to weeks), refrigeration at 4°C (39°F) is acceptable.
- Lyophilized peptides are typically stable at room temperature for several weeks, making it suitable for moderate-term storage.
- For long-term storage (months to years), it’s best to freeze peptides at -80°C (-112°F). Freezing optimally preserves peptide stability for extended periods.
Reviews (0)
Research Use Only (RUO) Policy
"RUO" is an abbreviation for Research Use Only. It is a designation used primarily by the FDA (Food and Drug Administration) for products, often in vitro diagnostic (IVD) components like reagents or instruments, that are in the laboratory research phase of development and are not intended for clinical diagnostic use.
READ MORE
Reviews
There are no reviews yet.